开源证券给予昆药集团买入评级，公司信息更新报告：渠道改革纵深推进，以破求立夯实发展基础

Core Viewpoint - The report from Kaiyuan Securities on August 18 recommends a "buy" rating for Kun Pharmaceutical Group (600422.SH, latest price: 14.7 yuan) based on several positive factors [2] Group 1: Investment Thesis - The company is actively participating in the national centralized procurement, with an expectation that the pace of procurement will accelerate in the second half of 2025 [2] - The company is in a critical phase of channel expansion, aiming to break through existing challenges [2]